10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||||||||||||
| |||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
REGENERON PHARMACEUTICALS, INC. | |||
Ticker: REGN Fiscal Year: 2019 | |||
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME | |||
Period Ending Dec 31, 2019 10-K (Filed: Feb 7, 2020) | |||
| (In Thousands) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | |
| Statements of Operations | |||
| Revenues: | |||
| Revenues | $ 7,863,400 | 6,710,800 | 5,872,200 |
| Expenses: | |||
| Research and development | 3,036,600 | 2,186,100 | 2,075,100 |
| Selling, general, and administrative | 1,834,800 | 1,556,200 | 1,320,400 |
| Total expenses | 5,653,600 | 4,176,400 | 3,792,600 |
| Income from operations | 2,209,800 | 2,534,400 | 2,079,600 |
| Other income (expense): | |||
| Other income (expense), net | 249,500 | 47,300 | 24,000 |
| Interest expense | (30,200) | (28,200) | (25,100) |
| Total other income (expense) | 219,300 | 19,100 | (1,100) |
| Income before income taxes | 2,429,100 | 2,553,500 | 2,078,500 |
| Income tax expense | (313,300) | (109,100) | (880,000) |
| Net income | 2,115,800 | 2,444,400 | 1,198,500 |
| Net income per share - basic (in dollars per share) | 19.38 | 22.65 | 11.27 |
| Net income per share - diluted (in dollars per share) | 18.46 | 21.29 | 10.34 |
| Weighted average shares outstanding - basic (in shares) | 109,200 | 107,900 | 106,300 |
| Weighted average shares outstanding - diluted (in shares) | 114,600 | 114,800 | 115,900 |
| Statements of Comprehensive Income | |||
| Net income | 2,115,800 | 2,444,400 | 1,198,500 |
| Other comprehensive income (loss), net of tax: | |||
| Unrealized gain (loss) on marketable securities | 35,900 | (7,000) | 12,700 |
| Unrealized (loss) gain on cash flow hedges | (2,500) | ||
| Unrealized (loss) gain on cash flow hedges | 700 | 800 | |
| Comprehensive income | 2,149,200 | 2,438,100 | 1,212,000 |
| Project | |||
| Sanofi | |||
| Product and Service | |||
| Product and service, other | |||
| Revenues | 1,426,800 | 1,111,100 | 877,200 |
| Bayer | |||
| Revenues | 1,188,800 | 1,076,700 | 938,100 |
| Other | |||
| Revenues | 413,400 | 416,800 | 338,400 |
| Product and Service | |||
| Product | |||
| Revenues | 4,834,400 | 4,106,200 | 3,718,500 |
| Cost of goods sold | 362,300 | 180,000 | 202,500 |
| Collaboration and contract manufacturing | |||
| Cost of goods sold | 419,900 | 254,100 | 194,600 |
| External Links | |
| REGENERON PHARMACEUTICALS, INC. (REGN) Fiscal Year 2019 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |